MA40617B1 - Formulation comprenant glycopyrrolate, procédé et appareil - Google Patents

Formulation comprenant glycopyrrolate, procédé et appareil

Info

Publication number
MA40617B1
MA40617B1 MA40617A MA40617A MA40617B1 MA 40617 B1 MA40617 B1 MA 40617B1 MA 40617 A MA40617 A MA 40617A MA 40617 A MA40617 A MA 40617A MA 40617 B1 MA40617 B1 MA 40617B1
Authority
MA
Morocco
Prior art keywords
glycopyrrolate
jet
magnesium stearate
formulation
milled
Prior art date
Application number
MA40617A
Other languages
English (en)
French (fr)
Other versions
MA40617A (fr
Inventor
Fergus Manford
Original Assignee
Vectura Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=51542160&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA40617(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Vectura Ltd filed Critical Vectura Ltd
Publication of MA40617A publication Critical patent/MA40617A/fr
Publication of MA40617B1 publication Critical patent/MA40617B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4704—2-Quinolinones, e.g. carbostyril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1688—Processes resulting in pure drug agglomerate optionally containing up to 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5015—Organic compounds, e.g. fats, sugars
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5192—Processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/04—Drugs for disorders of the respiratory system for throat disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Otolaryngology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Physics & Mathematics (AREA)
  • Nanotechnology (AREA)
  • Optics & Photonics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
MA40617A 2014-09-09 2015-09-09 Formulation comprenant glycopyrrolate, procédé et appareil MA40617B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP14184164 2014-09-09
PCT/EP2015/070660 WO2016038116A1 (en) 2014-09-09 2015-09-09 Formulation comprising glycopyrrolate, method and apparatus

Publications (2)

Publication Number Publication Date
MA40617A MA40617A (fr) 2017-07-19
MA40617B1 true MA40617B1 (fr) 2020-05-29

Family

ID=51542160

Family Applications (2)

Application Number Title Priority Date Filing Date
MA40617A MA40617B1 (fr) 2014-09-09 2015-09-09 Formulation comprenant glycopyrrolate, procédé et appareil
MA050680A MA50680A (fr) 2014-09-09 2015-09-09 Formulation comprenant glycopyrrolate, procédé et appareil

Family Applications After (1)

Application Number Title Priority Date Filing Date
MA050680A MA50680A (fr) 2014-09-09 2015-09-09 Formulation comprenant glycopyrrolate, procédé et appareil

Country Status (38)

Country Link
US (2) US10532041B2 (es)
EP (2) EP3689332A1 (es)
JP (1) JP6502501B2 (es)
KR (1) KR101927960B1 (es)
CN (1) CN106604720B (es)
AP (1) AP2017009777A0 (es)
AR (1) AR101793A1 (es)
AU (1) AU2015314272B2 (es)
BR (1) BR112017003888B1 (es)
CA (1) CA2960694C (es)
CL (1) CL2017000560A1 (es)
CO (1) CO2017003056A2 (es)
CY (1) CY1124569T1 (es)
DK (1) DK3191081T3 (es)
DO (1) DOP2017000065A (es)
EA (1) EA037332B1 (es)
EC (1) ECSP17021465A (es)
ES (1) ES2793905T3 (es)
HR (1) HRP20201005T1 (es)
HU (1) HUE049339T2 (es)
IL (1) IL250427A0 (es)
LT (1) LT3191081T (es)
MA (2) MA40617B1 (es)
MX (1) MX2017003080A (es)
MY (1) MY181647A (es)
NZ (1) NZ728435A (es)
PH (1) PH12017500303A1 (es)
PL (1) PL3191081T3 (es)
PT (1) PT3191081T (es)
RS (1) RS60299B1 (es)
SG (1) SG11201700536XA (es)
SI (1) SI3191081T1 (es)
SV (1) SV2017005403A (es)
TN (1) TN2017000077A1 (es)
TW (1) TWI602566B (es)
UA (1) UA115958C2 (es)
WO (1) WO2016038116A1 (es)
ZA (1) ZA201700658B (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3595631A1 (en) * 2017-03-15 2020-01-22 Vectura Limited Method and formulation
CN112137957B (zh) * 2019-06-26 2022-07-29 长风药业股份有限公司 一种药用吸入气雾剂及其制备方法
WO2021143785A1 (zh) * 2020-01-15 2021-07-22 四川海思科制药有限公司 一种含茚达特罗的吸入气雾剂药物组合物及其制备方法

Family Cites Families (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2956062A (en) 1959-02-26 1960-10-11 Robins Co Inc A H Esters of amino alcohols
SE9302777D0 (sv) 1993-08-27 1993-08-27 Astra Ab Process for conditioning substances
GB9501841D0 (en) 1995-01-31 1995-03-22 Co Ordinated Drug Dev Improvements in and relating to carrier particles for use in dry powder inhalers
GB9808470D0 (en) 1998-04-22 1998-06-17 Smithkline Beecham Plc Novel process and apparatus
GB9826284D0 (en) 1998-12-01 1999-01-20 Rhone Poulence Rorer Limited Process
GB9826286D0 (en) 1998-12-01 1999-01-20 Rhone Poulence Rorer Limited Process
GB0008660D0 (en) 2000-04-07 2000-05-31 Arakis Ltd The treatment of respiratory diseases
JP2004515260A (ja) 2000-04-11 2004-05-27 デュラ・ファーマシューティカルズ・インコーポレイテッド 物理的に安定化された乾燥粉末製剤
WO2002008470A1 (en) 2000-07-20 2002-01-31 Campina B.V. Method for producing a crystalline tableting additive, additive thus obtained and use thereof
WO2002043702A2 (en) 2000-11-30 2002-06-06 Vectura Limited Pharmaceutical compositions for inhalation
GB0030074D0 (en) 2000-12-08 2001-01-24 Univ London Pharmacy Particulate inhalation carrier
DE10212264A1 (de) 2002-03-20 2003-10-02 Boehringer Ingelheim Pharma Kristallines Mikronisat, Verfahren zu dessen Herstellung und dessen Verwendung zur Herstellung eines Arzneimittels
US7309707B2 (en) 2002-03-20 2007-12-18 Boehringer Ingelheim Pharma Gmbh & Co. Kg Crystalline micronisate, process for the manufacture thereof and use thereof for the preparation of a medicament
ITMI20022674A1 (it) 2002-12-18 2004-06-19 Chiesi Farma Spa Procedimento per la preparazione di formulazioni sterili a base di principi attivi farmaceutici cristallini micronizzati da somministrare come sospensioni acquose per inalazione.
US20040121003A1 (en) 2002-12-19 2004-06-24 Acusphere, Inc. Methods for making pharmaceutical formulations comprising deagglomerated microparticles
US7188993B1 (en) * 2003-01-27 2007-03-13 Harold W Howe Apparatus and method for resonant-vibratory mixing
GB0327723D0 (en) 2003-09-15 2003-12-31 Vectura Ltd Pharmaceutical compositions
GB0321607D0 (en) 2003-09-15 2003-10-15 Vectura Ltd Manufacture of pharmaceutical compositions
JO3102B1 (ar) 2004-03-17 2017-09-20 Chiesi Framaceutici S P A صيغ صيدلانية لوسائل استنشاق بها مسحوق جاف تشتمل على مكون فعال بقوة منخفضة الجرعة
GB0409703D0 (en) * 2004-04-30 2004-06-02 Vectura Ltd Pharmaceutical compositions
GB0410398D0 (en) 2004-05-10 2004-06-16 Arakis Ltd The treatment of respiratory disease
GB0410399D0 (en) * 2004-05-10 2004-06-16 Arakis Ltd The treatment of respiratory disease
GB0411056D0 (en) 2004-05-18 2004-06-23 Novartis Ag Organic compounds
GB0425758D0 (en) 2004-11-23 2004-12-22 Vectura Ltd Preparation of pharmaceutical compositions
US20060292077A1 (en) 2005-03-18 2006-12-28 Zhao Jonathon Z Dendritic and star-shaped contrast agents for medical devices and bioabsorbable radiopaque bulk material and method for producing same
GB0523653D0 (en) 2005-11-21 2005-12-28 Novartis Ag Organic compounds
CA2614409C (en) 2005-07-07 2014-05-20 Nanotherapeutics, Inc Process for milling and preparing powders and compositions produced thereby
GB0523654D0 (en) 2005-11-21 2005-12-28 Novartis Ag Organic compounds
GB0523655D0 (en) 2005-11-21 2005-12-28 Novartis Ag Organic compounds
GB0523656D0 (en) 2005-11-21 2005-12-28 Novartis Ag Organic compounds
GB0525254D0 (en) 2005-12-12 2006-01-18 Jagotec Ag Powder compositions for inhalation
GB0613161D0 (en) * 2006-06-30 2006-08-09 Novartis Ag Organic Compounds
JP5283835B2 (ja) * 2006-07-06 2013-09-04 東京エレクトロン株式会社 マイクロ波プラズマ処理装置及びマイクロ波プラズマ処理装置用ゲートバルブ
EP1894568A1 (en) 2006-08-31 2008-03-05 Novartis AG Pharmaceutical compositions for the treatment of inflammatory or obstructive airway diseases
EP1944018A1 (en) 2007-01-10 2008-07-16 CHIESI FARMACEUTICI S.p.A. Micronised particles of low-dosage strength active agents for powder formulations for inhalation
GB0702456D0 (en) 2007-02-08 2007-03-21 Astrazeneca Ab New combination
KR20100095437A (ko) 2007-11-07 2010-08-30 아스트라제네카 아베 아스코르브산 유도체를 포함하는 건조 분말 제제
KR20100095587A (ko) 2007-12-13 2010-08-31 노파르티스 아게 유기 화합물
BRPI0821186A2 (pt) 2007-12-13 2015-06-16 Novartis Ag Compostos orgânicos
US8235314B2 (en) 2009-02-12 2012-08-07 Linde Aktiengesellschaft Nonequilibrium humidity control for jet milling
WO2010115937A1 (en) 2009-04-09 2010-10-14 Novartis Ag Process for preparing pyrrolidinium salts
SG175312A1 (en) 2009-04-24 2011-11-28 Iceutica Pty Ltd Method for the production of commercial nanoparticle and microparticle powders
TR201811349T4 (tr) * 2010-04-01 2018-09-21 Chiesi Farm Spa İnhalasyon i̇çi̇n kuru toz taşiyici parti̇külleri̇n hazirlanmasi i̇çi̇n proses.
NO2560611T3 (es) 2010-04-21 2018-06-02
JP5792308B2 (ja) 2010-08-31 2015-10-07 グラクソ グループ リミテッドＧｌａｘｏ Ｇｒｏｕｐ Ｌｉｍｉｔｅｄ 水分制御特性を示す乾燥粉末吸入薬物製品及びその投与方法
EP2749277A3 (en) 2011-02-17 2014-08-27 Cipla Limited Combination of glycopyrronium and vilanterol
JO3510B1 (ar) * 2011-03-04 2020-07-05 Heptares Therapeutics Ltd استخدام جلايكوبيرولات لعلاج عدم انتظام دقات القلب
SG194896A1 (en) 2011-05-17 2013-12-30 Pearl Therapeutics Inc Compositions, methods & systems for respiratory delivery of two or more active agents
GB201205632D0 (en) 2012-03-30 2012-05-16 Vectura Ltd Method and apparatus
EA201590019A1 (ru) 2012-07-05 2015-09-30 Арвен Айлак Санайи Ве Тиджарет А.С. Ингаляторы сухого порошка, содержащие носитель, отличный от лактозы
WO2014007767A1 (en) 2012-07-05 2014-01-09 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Dry powder inhalers comprising a carrier other than lactose and a ternary component
DE102012211907A1 (de) * 2012-07-09 2014-01-09 Robert Bosch Gmbh Drehschlagschrauber mit einem Schlagwerk
GB201305825D0 (en) 2013-03-28 2013-05-15 Vectura Ltd New use
RU2015154720A (ru) 2013-05-22 2017-06-27 Перл Терапьютикс, Инк. Композиции, способы и системы для респираторной доставки трех или более активных средств
US20160317391A1 (en) 2013-12-17 2016-11-03 Merck Sharp & Dohme Corp. Media milling process for the manufacture of active pharmaceutical ingredients in propellants

Also Published As

Publication number Publication date
UA115958C2 (uk) 2018-01-10
PT3191081T (pt) 2020-05-29
BR112017003888A2 (pt) 2018-01-23
BR112017003888B1 (pt) 2022-11-16
EP3191081B1 (en) 2020-03-25
CA2960694C (en) 2021-05-04
CO2017003056A2 (es) 2017-07-11
PH12017500303B1 (en) 2017-07-03
RS60299B1 (sr) 2020-07-31
US20170258762A1 (en) 2017-09-14
ECSP17021465A (es) 2017-05-31
TN2017000077A1 (en) 2018-07-04
KR20170054458A (ko) 2017-05-17
LT3191081T (lt) 2020-07-10
EA201790544A1 (ru) 2017-09-29
SG11201700536XA (en) 2017-02-27
ES2793905T3 (es) 2020-11-17
IL250427A0 (en) 2017-03-30
CY1124569T1 (el) 2022-03-24
PH12017500303A1 (en) 2017-07-03
HRP20201005T1 (hr) 2020-10-16
JP6502501B2 (ja) 2019-04-17
US10532041B2 (en) 2020-01-14
CL2017000560A1 (es) 2018-03-16
MX2017003080A (es) 2017-11-15
KR101927960B1 (ko) 2018-12-11
AR101793A1 (es) 2017-01-11
NZ728435A (en) 2017-11-24
DOP2017000065A (es) 2017-07-15
CN106604720B (zh) 2020-03-10
DK3191081T3 (da) 2020-06-15
ZA201700658B (en) 2022-05-25
JP2017527621A (ja) 2017-09-21
MY181647A (en) 2020-12-30
CA2960694A1 (en) 2016-03-17
TW201617072A (zh) 2016-05-16
SV2017005403A (es) 2017-08-23
US20200155506A1 (en) 2020-05-21
EP3689332A1 (en) 2020-08-05
MA40617A (fr) 2017-07-19
EP3191081A1 (en) 2017-07-19
CN106604720A (zh) 2017-04-26
EA037332B1 (ru) 2021-03-15
AU2015314272B2 (en) 2017-11-23
WO2016038116A1 (en) 2016-03-17
SI3191081T1 (sl) 2020-07-31
TWI602566B (zh) 2017-10-21
MA50680A (fr) 2020-08-05
HUE049339T2 (hu) 2020-09-28
PL3191081T3 (pl) 2020-09-07
AP2017009777A0 (en) 2017-03-31
AU2015314272A1 (en) 2017-02-09

Similar Documents

Publication Publication Date Title
MA55380A (fr) Dérivé hétéroaryle, son procédé de production et composition pharmaceutique le comprenant en tant que constituant efficace
JP2017500760A5 (es)
MA47816A (fr) Composition pharmaceutique comprenant du sélexipag
WO2015157660A3 (en) Mechanism for performing lockless rolling upgrade of nosql database
MA44209A (fr) Procede de preparation d'un oligomere phosphorodiamidate substantiellement diastereomeriquement pure, un oligomere phosphorodiamidate faite par un tel procede et une composition pharmaceutique comprenant un tel oligomere phosphorodiamidate
FR3027367B1 (fr) Support d'equipement d'une turbomachine comprenant un reducteur magnetique
MA40617B1 (fr) Formulation comprenant glycopyrrolate, procédé et appareil
MA42964A (fr) Préparation pharmaceutique anti-vieillissement
NZ739621A (en) Compositions and methods for treating and preventing neurodegenerative disorders
DK3305755T3 (da) Ny fremgangsmåde til at fremstille stærkt umættede fedtsyreestere
JP2019047960A5 (es)
EP3537155A4 (en) METHOD FOR DETERMINING THE RISK OF MORBUS ALZHEIMER
WO2015181802A3 (en) Oral pharmaceutical composition of isotretinoin
MA41852B1 (fr) Panneau pour véhicule comprenant une tôle d'acier revêtue localement renforcée
EP3328411A4 (en) RETARD AGGREGATE FORMULATIONS FOR GLAUCOMA
EP3641797A4 (en) PROCESS FOR THE PREPARATION OF A STANDARDIZED COMPOSITION OF ARJUNOGLUCOSIDE FROM THE BARK DETERMINALIA ARJUNA
SI3565552T1 (sl) Izboljšan postopek za pripravo rivaroksabana, ki vključuje nov intermediat
WO2016069542A3 (en) Lactone compounds and methods of making and using same
WO2014128728A3 (en) Solid forms of cabazitaxel and processes for preparation thereof
EP3400100A4 (en) PROCESS FOR THE PREPARATION OF 1,3-BANDANDIOL AND FOR THE OPTIONAL FURTHER PREPARATION OF (R) -3-HYDROXYBUTYL (R) -3-HYDROXYBUTYRATE
MA40990A (fr) Formulations de matrice pharmaceutique comprenant du fumarate de diméthyle
MX2019000977A (es) Composiciones farmacéuticas a base de curcumina y procedimientos para su fabricación.
EP3615204A4 (en) PROCESS FOR PREPARING DEUTERATED ETHANOL FROM D2O
WO2018094035A3 (en) Ligand ionophore conjugates
MA43122A (fr) Composition de préparation solide contenant du pranlukast à biodisponibilité améliorée et procédé pour sa préparation